# US 2010/0168117 A1 · A process for the preparation of the stable, amorphous calcium salt of (6s)-n(5)-methyl-5,6,7,8-tetrahydrofolic acid

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168117 A1
- Document ID: US20100168117A1
- Status: Published application
- Kind: A1
- Application number: 12/601,207
- Filed: 2008-05-29
- Published: 2010-07-01
- Earliest claimed: 2007-05-30
- Assignees: Cerbios-Pharma SA
- Inventors: Raffella Manzotti; Moreno Morosoli
- Web page: https://patentgrep.com/patent/US20100168117A1

## CPC

- C07D 475/04: with a nitrogen atom directly attached in position 2
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A process for the preparation of an aqueous solution of the calcium salt of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid, whereby (6S)-5,6,7,8-tetrahydrofolic acid having a content of the corresponding (6R)-diastereoisomer in the range from 4% by weight to 8% by weight is methylated in water comprises: treating the methylated reaction mixture with calcium chloride; crystallizing the calcium salt of (6RS)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid from the resulting aqueous solution; and obtaining an aqueous solution of the calcium salt of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid.

## Claims

### Claim at position 1

1-17. (canceled)

### Claim 18

A process for the preparation of an aqueous solution of the calcium salt of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid of the formula III,
whereby (6S)-5,6,7,8-tetrahydrofolic acid of the formula II having a content of the corresponding (6R)-diastereoisomer in the range from 4% by weight to 8% by weight is methylated in water,
comprising
adding to the methylated reaction mixture from 0.70 to 0.82 equivalents of calcium chloride relative to the THF,
crystallizing selectively and separating the calcium salt of (6RS)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid from the resulting aqueous solution, and
obtaining an aqueous solution of the calcium salt of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid of the formula III having a content of the corresponding (6R)-diastereoisomer of ≦2% by weight.

### Claim 19 (depends on 18)

The process according to claim 18, wherein the calcium chloride is added in solid form or in the form of an aqueous solution.

### Claim 20 (depends on 18)

The process of claim 18, wherein the selective crystallization of the calcium salt of (6RS)-N(5)-methyl-5,6,7, 8-tetrahydrofolic acid is realized by seeding with previously prepared crystals of the calcium salt of (6RS)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid, followed by a lowering of the temperature from room temperature to a temperature in the range from 3° C. to 5° C., and maintaining that temperature for 16 to 18 hours.

### Claim 21

A process for the preparation of stable, crystalline (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid of the formula IV,
comprising
adding to an aqueous solution of the calcium salt of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid of the formula III having a content of the corresponding (6R)-diastereoisomer of ≦2% by weight either acetic acid or a sulfonic acid in such an amount, until a pH-value of 5.5 is obtained,
warming the resulting solution to a temperature from 44° C. to 46° C.,
adding to the warmed solution either acetic acid or a sulfonic acid in such an amount, until a pH-value in the range from 4.3 to 4.4 is obtained, whereby the crystallization of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid of the formula IV begins, and whereby during this crystallization the pH-value is maintained in the range from 4.3 to 4.4 by continuous addition of either acetic acid or of a sulfonic acid, and
filtering off the resulting crystalline solid at a temperature in the range from 44° C. to 46° C. and isolating it.

### Claim 22 (depends on 21)

The process of claim 21, wherein the obtained crystalline solid is washed with water having a temperature of about 40° C.

### Claim 23 (depends on 21)

The process of claim 21, wherein the sulfonic acid is p-toluene sulfonic acid.

### Claim 24 (depends on 18, 21)

The process of claim 21, wherein the aqueous solution of the calcium salt of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid of the formula III having a content of the corresponding (6R)-diastereoisomer of 2% by weight is prepared according to the process of claim 18.

### Claim 25

Stable, crystalline (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid of the formula IV having a diastereoisomeric purity of at least 99%.

### Claim 26 (depends on 25)

Stable, crystalline (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid according to claim 25, having:
the differential scanning calorimetric profile (DSC) as shown in FIG. 2a,
the thermogravimetric profile (TGA) as shown in FIG. 2b,
the X-ray powder diffraction diagram as shown in FIG. 3a, and
the 2 Theta-values having an error of about ±0.2 degree as shown in FIG. 3b.

### Claim 27 (depends on 25)

Stable, crystalline (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid according to claim 25, wherein the corresponding X-ray powder diffraction diagram has the following characteristic 2 Theta-values:
15.0
15.6
17.4
18.7
19.9
22.2
24.3 and
29.5.

### Claim 28 (depends on 25)

A dietary supplement comprising the stable, crystalline (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid of formula IV according to claim 25 as an active component.

### Claim 29 (depends on 21)

A process for the preparation of the stable, amorphous calcium salt of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid of Formula V,
comprising
preparing crystalline (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid of the formula IV according to the process according to claim 21,
suspending the resulting product in water at a temperature from 35° C. to 41° C.,
adding to the resulting suspension NaOH solution in portions and in such an amount to achieve a pH of 6.7 to 6.9,
adding to the resulting solution 0.90 equivalents of calcium chloride, relative to the amount of the compound of formula IV,
adjusting the concentration of the compound of formula IV in the resulting mixture to a value in the range from 14% by weight to 16% by weight by the addition or removal of water,
starting the precipitation of the calcium salt of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid of the formula V by the addition of a small amount of previously prepared compound of formula V,
maintaining the resulting mixture at a temperature of 40° C. for 1 hour,
lowering the temperature from 40° C. to a temperature of 23° C. over about two hours,
maintaining the temperature at 23° C. for 16 to 18 hours, and
isolating the resulting solid.

### Claim 30 (depends on 29)

The process of claim 29, wherein the resulting solid is washed with water having a temperature of about 10° C., the washed solid is suspended at room temperature in 94% aqueous ethanol and isolating the resulting solid by means of filtration.

### Claim 31 (depends on 29)

The process of claim 29, wherein the calcium chloride is added in solid form or in the form of an aqueous solution.

### Claim 32 (depends on 21)

Stable, amorphous calcium salt of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid of formula V,
produced according to the method comprising:
suspending in water crystalline (6S)-N(5)-methyl-5,6,7,8-tetra-hydrofolic acid of formula IV, prepared according to the process according to claim 21, whereby the water has a temperature from 35° C. to 41° C.,
adding to this suspension a NaOH solution in portions and in such an amount until a pH value in the range from 6.7 to 6.9 is obtained,
adding to the resulting solution 0.90 equivalents of calcium chloride, relative to the amount of the compound of formula IV,
adjusting the concentration of the compound of formula IV in the resulting mixture by addition or by removal of water to a value in the range of from 14% by weight to 16% by weight,
starting the precipitation of the calcium salt of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid of the formula V by the addition of a small amount of previously prepared compound of formula V,
maintaining the resulting mixture for about 1 hour at a temperature of 40° C.,
lowering the temperature from 40° C. to 23° C. over about 2 hours,
maintaining a temperature of 23° C. for about 16 to 18 hours, and
isolating the resulting solid.

### Claim 33 (depends on 30)

Stable, amorphous calcium salt of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid produced according to the process of claim 30.

### Claim 34 (depends on 32)

Stable, amorphous calcium salt of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid according to claim 32, having:
the differential scanning calorimetric profile (DSC) of FIG. 4a,
the thermogravimetric profile (TGA) of FIG. 4b,
the X-ray powder diffraction diagram of FIG. 5, and
the Raman spectrum of FIG. 6.

### Claim 35 (depends on 25)

A method of treating a human being or an animal suffering from tumors comprising administering to said human being or animal a medicament comprising stable crystalline (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid of formula IV according to claim 25 as an active component.

### Claim 36 (depends on 35)

The method of claim 35, wherein the medicament is administered in combination with another cancer controlling agent.

### Claim 37 (depends on 25)

A method of reducing the toxicity of a cancer controlling compound comprising administering besides said cancer controlling compound a medicament comprising stable crystalline (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid of formula IV according to claim 25 as an active component.

### Claim 38 (depends on 25)

A method of protecting human or animal cells comprising administering to said human being or animal a medicament comprising stable crystalline (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid of formula IV according to claim 25 as an active component.

### Claim 39 (depends on 31)

Stable, amorphous calcium salt of (6S)-N(5)-methyl-5,6,7,8-tetrahydrofolic acid produced according to the process of claim 31.
